RCT | Atezolizumab in platinum-ineligible NSCLC elevates median survival to 10.3 months vs. 9.2 months with chemotherapy

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study – The Lancet (link to abstract – $ for full-text)

News Release: Immunotherapy for ‘difficult to treat’ lung cancer patients improves long-term survival – University College London